🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats authors on the #ASH23 abstract “Intermittent Sargramostim Administration Expands Proliferating Naïve T Cells, Tregs, HLA-DR+ PD-L1+ Monocytes & MDSCs: Results from a RCT of GM-CSF in Patients with Peripheral Artery Disease” #sargramostim #GMCSF bit.ly/484LQ7o

Results of a prospective, randomized, placebo-controlled study of inhaled Leukine® in non-hospitalized COVID-19 patients suggest its potential role as a host-directed immunomodulator. For more, read a press release bit.ly/4arYlM5, or abstract bit.ly/4aHVcrR here

Congratulations authors on “GM-CSF, G-CSF, or no cytokine therapy with anti-GD2 #immunotherapy for high-risk #neuroblastoma” highlighting the importance of combination #sargramostim & anti-GD2 #mAbs #dinutuximab #naxitamab bit.ly/46YRbvW Read more:bit.ly/3S09tHL

Well done, authors, on “Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer.” Read full text: bit.ly/3Hu98bx #cancer #irAE #immunotherapy #sargramostim #GMCSF

Today is Rare Disease Day 2024. We are pleased to support research in this important area through sponsorship of the Rare Disease Clinical Trials Conference in Dublin, Ireland. #ShowYourStripes #RareDiseaseDay

Pricing implications in the US on small biotechs requires close management of gross to net. Join Jake McDowell, VP and Head of Market Access and Pricing at @PartnterTX at the 2024 World EPA Congress in Amsterdam on March 12-13 to discuss. bit.ly/3Tyx3xl #EPAConf

Sargramostim received Japanese PDMA approval as Sargmalin® to treat autoimmune pulmonary alveolar proteinosis. Sargramostim to be manufactured by PartnerTx and marketed by Nobelpharma Co. Ltd. #aPAP #sargramostim #GMCSF #Japan Press release: bit.ly/4ar2lME

Investigators of the EA6141 phase 2/3 trial are exploring #nivolumab, #ipilimumab, and #sargramostim for patients with unresectable stage III or stage IV #melanoma.Additional details from the principal investigator: bit.ly/3TXT7Ah #cancerresearch

Excited to see continued investigation and literature of Leukine with immune checkpoint inhibitors for patients with #melanoma and GI immune-related adverse effects. Press Release: bit.ly/3TYAaNU #sargramostim #GMCSF #immunotherapy #ipilumumab #nivolumab #irAE

Thank you to the patients, families, and investigators for your continued commitment to advance melanoma research #melanoma #cancerresearch #immunotherapy #ipilumumab #nivolumab #sargramostim #GMCSF Learn more about this important trial: bit.ly/ea6141melanoma

PartnerTx is honored to sponsor the 2024 Pap Foundation Golfing for a Cure Charity Golf Tournament. #PAPawareness

Congratulations to the Task Force on the first published guidelines for the diagnosis and management of #pulmonaryalveolarproteinosis.

Partner Therapeutics is excited to attend the Military Health Systems Research Symposium. Visit us at Booth #606. #MHSRS2024

Our heartfelt condolences on the loss of a pioneer in immunotherapy and melanoma research, Jeffrey S. Weber, PhD, MD. We celebrate his numerous contributions for patients and impact on clinical practice.

Partner Therapeutics supports #BloodCancerAwarenessMonth and #WorldLeukemiaDay. Together we can raise awareness. #LeukemiaAwareness

Join us at ERRS as Dr. Melanie Doyle-Eisele presents "Sargramostim improves survival and recovery from pancytopenia in [non-human primate] total body irradiation model with minimal supportive care" on Tues Sept 10 at 15:15 WEST. #sargramostim #GMCSF #radiation #myelosuppression

Please join #RadRes2024 Poster Session 1 - 9/15 at 1:45-2:30pm MST for "The lethality of radiation-induced sepsis and associated immune dysregulation highlight the importance of restoring lymphocyte and monocyte levels and function after total body irradiation."Radiation Research Society #GMCSF

Partner Therapeutics supports #ChildhoodCancerAwareness Month. We honor the children and families impacted by childhood cancer as well as the clinicians and researchers.

🧠 Sponsor Spotlight: PartnerTx On #NationalHealthcareDecisionsDay, we recognize the importance of informed, timely trauma care. Thanks to PartnerTx for advancing immunotherapy that supports decision-making in critical trauma settings. 🌐 partnertx.com #THOR #RDCR

IMREPLYS® (sargramostim, rhu GM-CSF) recommended for EU approval by the CHMP to treat exposure to haematopoietic acute radiation syndrome. Read more in the press release: bit.ly/4kUcdna